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A Matter of Timing
Therapy to Match Biology*
Bodh I. Jugdutt, MD, DM
Edmonton, Alberta, Canada
Cardiovascular remodeling is a major mechanism leading to
adverse outcome. The renin-angiotensin-aldosterone sys-
tem (RAAS), with angiotensin II as its primary effector
peptide, plays an important regulatory role in cardiovascular
remodeling. Most angiotensin II is formed via the
angiotensin-converting enzyme (ACE) pathway, providing
rationale for use of ACE inhibitors. Hypertension and
myocardial infarction are the top 2 causes of adverse
cardiovascular remodeling. Although hypertension results in
hypertrophic remodeling, myocardial infarction results in
predominantly dilative remodeling. A major goal of phar-
macotherapy is to limit cardiovascular remodeling and
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improve outcome. Evidence from randomized trials has
established ACE inhibitors as first-line therapy for hyper-
tension and post-infarction heart failure. Many studies have
shown that ACE inhibitors produce benefits beyond blood
pressure lowering and act at the tissue level to limit
remodeling. However, despite the wide use of ACE inhib-
itors, many patients continue to suffer from complications of
adverse remodeling.
How can we optimize benefits of pharmacotherapy? One
approach is the timing of therapy to match biological need
through chronotherapeutics, with attention to chronobiol-
ogy (the body’s biological time structure), circadian (24-h)
rhythms, and wake–sleep patterns (1,2). In this issue of the
Journal, Martino et al. (3) underscore the importance of
chronotherapy and diurnal timing in hypertrophic pressure-
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mainly during sleep time and propose administration of
ACE inhibitors such as captopril during sleep time for
optimal limitation of remodeling.
Homeostatic or chronobiological therapy? Until recently,
homeostatic therapy has been the dominant approach to
pharmacotherapy. It is based on the theory of constancy of
the milieu intérieur or internal environment advanced by
French Physiologist Claude Bernard (1813 to 1878) and the
underlying principle of homeostasis proposed by the Amer-
ican Physiologist Walter Bradford Cannon (1871 to 1945).
In this construct, deviation from set levels of biological
variables activate inherited homeostatic mechanisms that
provide moment-by-moment regulation and restore con-
stancy of the internal milieu. Homeostatic therapy is aimed
at maintaining constant drug blood/tissue levels over 24 h to
achieve sustained therapeutic benefit.
Advances in chronobiology since the 1960s suggest that
biological functions and processes are precisely organized in
time and space; inherited biological clocks and rhythms
regulate physiological and biochemical variables, patho-
physiology and disease progression, manifestation, symp-
tomatology, and response to therapy (1,2). Circadian
rhythms are controlled by a master clock residing in the
suprachiasmatic nuclei of the anterior hypothalamus and the
pineal gland. Timekeeping is determined by clock genes
(per1, per2, per3, bmal, clock, CRY) and melatonin. Circadian
clocks are adjusted through environmental cues such as
light–dark patterns that entrain the peaks and troughs in
synchrony with wake–sleep patterns. The human circadian
time structure shows typical peak times for several variables
(1,2) that are important for cardiovascular remodeling.
These include: 1) atrial natriuretic peptide, calcitonin,
cholesterol, and triglycerides during early sleep time;
2) growth hormone and melatonin during late sleep time;
and 3) cortisol, renin, angiotensin, aldosterone, cat-
echolamines, arterial compliance, blood pressure, platelet
aggregation, and blood viscosity in early wake time. Studies
suggest that circadian rhythms in peak severity of cardio-
vascular diseases match these peaks; for example, angina,
myocardial infarction, sudden cardiac death, ventricular
arrhythmias, thrombotic stroke, and hypertensive crises in
early wake time and Prinzmetal angina and hemorrhagic
stroke during sleep time. Disruption of circadian rhythms in
night-shift workers results in increased cardiovascular risk.
Studies have shown that inappropriately timed therapy can
be harmful.
Chronotherapy aims at synchronizing peak drug levels with
peaks of disease markers associated with adverse events and
avoiding adverse side effects during troughs. Chronotherapy
has already been applied in the treatment of several conditions,
including essential hypertension. Whereas blood pressure
peaks during wake time and dips during sleep time in essential
hypertension, the sleep-time dip is reduced, absent, or reversed
in secondary hypertension. Because nondippers in essential
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small a decline in blood pressure during sleep increases the risk
of left ventricular hypertrophy, therapy during sleep timemight
be beneficial in such patients. Although ACE inhibitors and
other antihypertensive therapies at night time have been shown
to restore diurnal dipping patterns in nondippers (4,5), the
effect of this approach on hypertrophy was never assessed.
Optimal timing of therapy for optimal benefit. Martino
et al. (3) addressed the important question of whether the
therapeutic benefit of ACE inhibitors on pressure-overload
hypertrophy exhibits significant diurnal variation. They com-
pared the effect of the short-acting ACE inhibitor captopril,
given intraperitoneally during sleep time (lights on at 7 AM) or
wake time (lights off at 7 PM) for 8 weeks, beginning 1 week
after surgical constriction of the descending aorta in young
mice. Previous studies already showed that chronic pressure
overload, induced by constriction of the ascending aorta in rats,
results in severe left ventricular hypertrophy associated with
normal renin and elevated ACE, and ACE inhibitors de-
creased hypertrophy and mortality. Martino et al. (3) demon-
strated that only sleep-time captopril limits cardiovascular
remodeling and improved systolic function. As expected, these
anti-remodeling effects of captopril were correlated with atten-
uation of tissue ACE mRNA levels that peaked at sleep time.
These benefits were independent of blood pressure lowering
because the decrease in blood pressure (on 24-h monitoring)
was similar with sleep- or day-time captopril, and the effect of
wake-time captopril on remodeling was identical to that of
placebo.
Several points arising from the study of Martino et al. (3)
deserve emphasis. First, the finding that the heart and its
vessels remodel during sleep time endorses diurnal timing of
pharmacotherapy for hypertrophic pressure-overload re-
modeling. Second, the finding that the efficacy of captopril
therapy on remodeling is critically dependent on timing
during sleep time is clinically highly relevant for optimal
benefit in pressure-overload conditions such as aortic ste-
nosis and aortic coarctation, and possibly hypertension.
Third, the overall findings support chronotherapy as an
effective approach for optimizing limitation of remodeling,
with the clear message that diurnal considerations may be
important for optimal therapeutic benefit.
A fourth point relates to the remodeling benefit observed
with a short-acting ACE inhibitor such as captopril. Other
ACE inhibitors such as enalapril, fosinopril, lisinopril,
perindopril, and ramipril are longer acting. An early study in
rats showed that short-term elevation of blood pressure
during sleep time, induced by repeated injections of angio-
tensin II over 4 h, resulted in a similar degree of hypertro-
phy as sustained blood pressure elevation produced by
continuous angiotensin II infusion (6), suggesting that the
acute load is sufficient to trigger chronic hypertrophy.
Therapy with short-acting agents may be a more effective
therapeutic approach and avoid adverse effects. The practice
of using multiple doses, slow-release, and long-acting drugs
to cover both wake and sleep times may need re-evaluation.There are several points in the study of Martino et al. (3)
that need verification. 1) Although molecular clocks that
orchestrate biological functions may be altered by disease
and therapy, the circadian clock genes mper2 and mbmal1
did not change with the interventions. 2) Other molecules
of the RAAS besides ACE (such as angiotensin II, aldo-
sterone, ACE-2, and angiotensin 1–8) that are pertinent for
cardiovascular remodeling may show diurnal variation.
3) Non-ACE pathways that can generate significant
amounts of angiotensin II under certain conditions includ-
ing ACE inhibition may show diurnal variation. 4) Reversal
of sleep/wake times in mice compared with humans may
result in different short-term and long-term effects on
diurnal molecular changes and remodeling. 5) Most exper-
imental studies demonstrating beneficial effects of ACE
inhibitors on remodeling gave the drug in drinking water,
which would have been ingested during wake time rather
than sleep time. 6) The benefits in young mice may differ in
older mice because age may affect circadian rhythms; this is
especially pertinent because the disease addressed is more
common in adult and elderly humans, as is the burden of
stroke and heart failure. 7) Although the mouse model has
its merits, confirmation in higher pre-clinical models (e.g.,
pig and dog) and humans might be desirable, especially
because human plasma renin, aldosterone, and angiotensin
have been reported to peak in early wake time (1,2).
In summary, timing of therapy on the basis of biology
makes sense, and chronotherapy is a potentially effective
approach for treating pressure-overload hypertrophic re-
modeling. Whether post–myocardial infarction remodeling
shows diurnal variations and benefits from chronotherapy
deserves study.
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